Home > Urology > EAU 2020 > Bladder Cancer > Understanding MIBC biology for novel treatment options

Understanding MIBC biology for novel treatment options

Presented By
Prof. Yohann Loriot, Université Paris-Saclay, France
Conference
EAU 2020
Trial
BLC2001; THOR; EV-301; EV-302; TROPHY-U-01; RANGE
Prof. Yohann Loriot (Université Paris-Saclay, France) discussed novel treatment options beyond immunotherapy [1]. He urged that a better understanding of the tumour biology is necessary to identify new targets and will facilitate precision medicine. Approaches derived from fundamental tumour biology have demonstrated clinical efficacy, including fibroblast growth factor receptor (FGFR) inhibitors and antibody-drug conjugates. In muscle-invasive bladder cancer (MIBC), somatic genetic alterations are potentially targetable, including mutations in FGFR3, HHRm, HER2, components of angiogenesis, and the epigenome. FGFR3 mutation is associated with luminal-papillary urothelial carcinoma; 70% of this pathology harbours somatic activating mutations, 20% exhibits gene rearrangement, and 10% overexpresses FGFR3. Specific FGFR inhibitors tested in urothelial cancer include BGJ398, rogaratinib, and erdafitinib. In th...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on